In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
“In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
“In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
See Video Here
